Courses

  • sfwd-courses

    Management of relapsed/refractory high-risk neuroblastoma (0.50 AMA PRA credits)

    The Postgraduate Institute for Medicine designates this educational activity for up to 1.00 AMA PRA Category 1 Credit(s)™. Physicians should…

    0
  • sfwd-courses

    ASH 2020: Therapeutic developments in ALL, NHL, and MM

    Learn from leading experts as they discuss the impact of key clinical data in ALL, NHL, and MM as presented…

    0
  • sfwd-courses

    ASH 2020: Therapeutic developments in ALL, NHL, and MM (1.25 AMA PRA credits)

    The Postgraduate Institute for Medicine designates this educational activity for 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only…

    0
  • sfwd-courses

    ASH 2020: Therapeutic developments in ALL, NHL, and MM (1.00 AMA PRA credits)

    The Postgraduate Institute for Medicine designates this educational activity for 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only…

    0
  • sfwd-courses

    ASH 2020: Therapeutic developments in ALL, NHL, and MM (0.75 AMA PRA credits)

    The Postgraduate Institute for Medicine designates this educational activity for 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only…

    0
  • sfwd-courses

    ASH 2020: Therapeutic developments in ALL, NHL, and MM (0.50 AMA PRA credits)

    Physician continuing medical education (AMA) The Postgraduate Institute for Medicine designates this educational activity for 0.50 AMA PRA Category 1…

    0
  • sfwd-courses

    Integrating neurological and pulmonary care for adolescents with SMA

    This activity is supported by an independent educational grant from Biogen MA, Inc. This activity is expired.   CME Information

    0
  • sfwd-courses

    Integrating neurological and pulmonary care for adolescents with SMA (1.00 AMA PRA credits)

    Physician continuing medical education (AMA) The Postgraduate Institute for Medicine designates this educational activity for 0.25 AMA PRA Category 1…

    0
  • sfwd-courses

    Integrating neurological and pulmonary care for adolescents with SMA (0.75 AMA PRA credits)

    Physician continuing medical education (AMA) The Postgraduate Institute for Medicine designates this educational activity for 0.75 AMA PRA Category 1…

    0
  • sfwd-courses

    Integrating neurological and pulmonary care for adolescents with SMA (0.50 AMA PRA credits)

    Physician continuing medical education (AMA) The Postgraduate Institute for Medicine designates this educational activity for 0.50 AMA PRA Category 1…

    0
  • sfwd-courses

    Integrating neurological and pulmonary care for adolescents with SMA (0.25 AMA PRA credits)

    Physician continuing medical education (AMA) The Postgraduate Institute for Medicine designates this educational activity for 0.25 AMA PRA Category 1…

    0
  • sfwd-courses

    Novel treatment strategies for upper tract urothelial cancer | Appropriate treatment selection in low-grade UTUC (0.50 ACPE credits)

    Accreditation Council for Pharmacy Education (ACPE) The Postgraduate Institute for Medicine designates this educational activity for 0.5 contact hours (0.05…

    0
  • sfwd-courses

    Novel treatment strategies for upper tract urothelial cancer | Appropriate treatment selection in low-grade UTUC (0.50 ANCC / 0.25 PRN credits)

    Continuing nursing education (ANCC-APRN) The maximum number of hours awarded for this continuing nursing education activity is 0.5 contact hours.…

    0
  • sfwd-courses

    Novel treatment strategies for upper tract urothelial cancer | Appropriate treatment selection in low-grade UTUC (0.50 AMA credits)

    Physician continuing medical education (AMA) The Postgraduate Institute for Medicine designates this educational activity for 0.5 AMA PRA Category 1…

    0
  • sfwd-courses

    Novel treatment strategies for upper tract urothelial cancer | Appropriate treatment selection in low-grade UTUC

    The interactive case, based on a patient in the real world, allows participants to follow a patient from assessment through…

    0
  • sfwd-courses

    New therapeutic strategies in the management of advanced-stage CTCL

    This activity has expired, so it is no longer possible to claim CME credits.

    0
  • sfwd-courses

    On the horizon: Immunotherapy strategies for relapsed/refractory high-risk neuroblastoma (on-demand)

    CME Information This webcast, On the horizon: Immunotherapy strategies for relapsed/refractory high-risk neuroblastoma, was originally presented as a live virtual,…

    0
  • sfwd-courses

    On the horizon: Immunotherapy strategies for relapsed/refractory high-risk neuroblastoma (1.5-0.75 on-demand ANCC-APRN credits)

    Continuing nursing education (ANCC-APRN) The maximum number of hours awarded for this continuing nursing education activity is 1.5 contact hours.…

    0
  • sfwd-courses

    On the horizon: Immunotherapy strategies for relapsed/refractory high-risk neuroblastoma (on-demand 1.50 AMA credits)

    Physician continuing medical education (AMA) The Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.5 AMA…

    0
  • sfwd-courses

    Novel treatment strategies for upper tract urothelial cancer | Expert insights on novel treatment options for UTUC (0.50 ACPE credits)

    Accreditation Council for Pharmacy Education (ACPE) The Postgraduate Institute for Medicine designates this educational activity for 0.5 contact hours (0.05…

    0